Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | DAO | P14920 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.51 |
| ▸ | IDO1 | P14902 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | NAMPT | P43490 | 1/20 | 0.47 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 2/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12428148 | 0.82 | ALDH1A1 (0.58) | FLT3KDM4EHPGDHSD17B10HRH4 | |
| SCHEMBL9288910 | 0.82 | CYP17A1 (0.44) | KDM4EHSD17B10HRH4HRH3ALDH1A1 | |
| SCHEMBL12427429 | 0.81 | ALDH1A1 (0.57) | KDM4EMAPTHPGDHSD17B10HRH4 | |
| SCHEMBL771326 | 0.80 | KDR (0.43) | KDM4EMAPTHPGDHSD17B10HRH4 | |
| SCHEMBL6389593 | 0.79 | PDGFRB (0.60) | FLT3KDM4EHPGDHRH4IDO1 | |
| SCHEMBL9688648 | 0.77 | HRH4 (0.49) | FLT3KDM4EHRH4HRH3MAP2K1 | |
| SCHEMBL7380785 | 0.76 | AHR (0.40) | FLT3KDM4EHRH4MAP2K1IDO1 | |
| SCHEMBL29145094 | 0.75 | HRH4 (0.52) | MAPTHRH4MAP2K1DRD3DRD2 | |
| SCHEMBL25667602 | 0.75 | HRH4 (0.59) | FLT3KDM4EMAPTHRH4POLB | |
| SCHEMBL10822252 | 0.73 | KCNA6 (0.53) | KDM4EHSD17B10SMN1; SMN2IDO1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362066-B2 | Compounds and methods for treating protein folding disorders | TREVENTIS CORPORATION (US) | 2013-01-29 | — | — | US | disclosed |
| US-8362066-B2 | Compounds and methods for treating protein folding disorders | TREVENTIS CORPORATION (US) | 2013-01-29 | — | — | US | disclosed |
| US-20100144821-A1 | COMPOUNDS AND METHODS FOR TREATING PROTEIN FOLDING DISORDERS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2010-06-10 | — | — | US | disclosed |
| US-20100144821-A1 | COMPOUNDS AND METHODS FOR TREATING PROTEIN FOLDING DISORDERS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2010-06-10 | — | — | US | disclosed |
| US-20050267303-A1 | Cyclic indole and heteroindole derivatives and methods for making and using as pharmaceuticals | ZENTARIS AG | 2005-12-01 | — | — | US | disclosed |
| EP-1423393-A1 | CYCLIC INDOLE AND HETEROINDOLE DERIVATIVES, THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | Zentaris GmbH (DE) | 2004-06-02 | — | — | EP | disclosed |
| US-20040039197-A1 | Cyclic indole and heteroindole derivatives and methods for making and using as pharmaceuticals | WATERWORKS, INC. | 2004-02-26 | — | — | US | disclosed |
| WO-2003020731-A1 | CYCLIC INDOLE AND HETEROINDOLE DERIVATIVES, THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | ZENTARIS GMBH (DE) | 2003-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144821-A1 | COMPOUNDS AND METHODS FOR TREATING PROTEIN FOLDING DISORDERS | SNCA, MAPT, APP | FLT3 4679/4885KDM4E 1608/4885MAPT 2/4885 |
| US-20050267303-A1 | Cyclic indole and heteroindole derivatives and methods for making and using as pharmaceuticals | IDO1, IDO2, INMT | FLT3 1155/4885KDM4E 3763/4885MAPT 226/4885 |
| US-20040039197-A1 | Cyclic indole and heteroindole derivatives and methods for making and using as pharmaceuticals | IDO1, IDO2, INMT | FLT3 1166/4885KDM4E 3807/4885MAPT 322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.